Clinical Trial Update: Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating stereotactic radiosurgery, NovoTTF-200M, and immune checkpoint inhibitors for melanoma brain metastases was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma Brain Metastases
• Melanoma of Unknown Primary
• Mucosal Melanoma
• Uveal Melanoma

Drugs mentioned

• Immune checkpoint inhibitors (unspecified)
• NovoTTF-200M

Snippet

Sponsor: Emory University | Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 1 | Status: TERMINATED